GCCL Signs MOU with KoNECT to Foster Mutual Collaboration in Clinical Research

▶ Strategic agreement aims to enhance clinical sample analysis quality and facilitate technology exchange

Global clinical sample analysis organization GCCL (Global Clinical Central Lab, CEO Kwan-Goo Cho) announced on July 30 that it has signed a Memorandum of Understanding (MOU) with the Korea National Enterprise for Clinical Trials (KoNECT, President In-Seok Park) to promote mutual collaboration in clinical research and support the development of Korea’s pharmaceutical industry.

The signing ceremony took place at GCCL headquarters on July 29, with key representatives from both organizations—including KoNECT President In-Seok Park and GCCL CEO Kwan-Goo Cho—in attendance. Both parties expressed a strong commitment to advancing Korea’s clinical trial ecosystem and accelerating new drug development through collaborative efforts. This agreement lays the groundwork for enhancing the quality of clinical sample analysis in Korea while building a foundation for policy and technological cooperation to improve global competitiveness.

Key areas of cooperation under the MOU include:

• - Establishing institutional frameworks and policy collaboration to strengthen clinical sample analysis capabilities

• - Sharing up-to-date medical and clinical insights related to sample analysis and other key topics

• - Co-developing training and educational programs and promoting academic and technical exchanges

• - Collaborating on domestic and international promotion by leveraging each other’s networks and infrastructure

• - Exploring additional areas of mutual interest

• 
  

This MOU is especially meaningful as it represents a strategic collaboration between a government-backed clinical trial support institution and one of Korea’s leading central labs specializing in clinical sample analysis. Both parties aim to jointly develop institutional foundations and implement practical initiatives to elevate Korea’s clinical trial capabilities and enhance its global competitiveness in new drug development.

President In-Seok Park of KoNECT remarked, “This agreement marks a significant milestone in building a practical collaboration model that links policy with field expertise. We will continue to work closely with industry stakeholders to enhance clinical trial quality and strengthen the global competitiveness of Korea’s biopharmaceutical sector.”

GCCL CEO Kwan-Goo Cho added, “We are honored to partner with KoNECT to raise the standards of clinical sample analysis and support the global advancement of Korea’s pharmaceutical and biotech industries. Leveraging our world-class analytical capabilities, we will continue to expand strategic partnerships with public institutions and deliver differentiated sample analysis services to global markets.”

GCCL is a GCLP (Good Clinical Laboratory Practice)–certified central lab that provides tailored clinical sample analysis services aligned with global standards across all clinical phases, from Phase I to Phase IV. With advanced platforms including digital PCR (ddPCR), GCCL supports clients across Korea, the broader Asia-Pacific region, and worldwide by offering high-quality bioanalytical services and method development capabilities.